A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Advanced Solid Tumor · Diffuse Large B Cell Lymphoma · Lymphoma, T-Cell · Mesothelioma, Malignant · Prostatic Neoplasms, Castration-Resistant · Endometrial Cancer · Ovarian Clear Cell Carcinoma · Metastatic Castration-resistant Prostate Cancer
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 300 (planned)
- Started
- Sep 18, 2019
- Main results expected
- Feb 27, 2030
- Fully finished
- Feb 27, 2030
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Tulmimetostat Monotherapy Phase 1: Frequency of Dose-limiting toxicities (DLTs)
Measured over: DLTs assessed during Cycle 1 (cycle = 28 days)
Tulmimetostat Monotherapy Phase 2: Overall response rate (ORR)
Measured over: Up to 30 months
Cohort M8 Part 1: Frequency of Dose-limiting toxicities (DLTs)
Measured over: DLTs assessed during Cycle 1 (cycle = 28 days)
Cohort M8 Part 2: Prostate-Specific Antigen 50 (PSA50) Response
Measured over: Up to 30 months
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT04104776 · record last updated 2026-08-19 · checked 2026-11-09 15:47 UTC